{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,17]],"date-time":"2026-05-17T09:09:21Z","timestamp":1779008961884,"version":"3.51.4"},"reference-count":124,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Behavioural Brain Research"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.bbr.2026.116120","type":"journal-article","created":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T07:15:54Z","timestamp":1771658154000},"page":"116120","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Parkinson\u2019s disease biomarkers: bridging the gap between diagnosis and treatment"],"prefix":"10.1016","volume":"505","author":[{"given":"Vaibhav A.","family":"Chakkarwar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yogesh A.","family":"Kulkarni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.bbr.2026.116120_bib1","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1001\/jama.2019.22360","article-title":"Diagnosis and treatment of Parkinson disease: a review","volume":"323","author":"Armstrong","year":"2020","journal-title":"Jama"},{"issue":"1","key":"10.1016\/j.bbr.2026.116120_bib2","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1002\/mds.23795","article-title":"Neuropathology of sporadic Parkinson\u2019s disease: evaluation and changes of concepts","volume":"27","author":"Jellinger","year":"2012","journal-title":"Mov. Disord."},{"issue":"6","key":"10.1016\/j.bbr.2026.116120_bib3","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1002\/ana.21995","article-title":"Clinical progression in Parkinson disease and the neurobiology of axons","volume":"67","author":"Cheng","year":"2010","journal-title":"Ann. Neurol."},{"issue":"6","key":"10.1016\/j.bbr.2026.116120_bib4","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1212\/WNL.0000000000002350","article-title":"Accuracy of clinical diagnosis of Parkinson disease: a systematic review and meta-analysis","volume":"86","author":"Rizzo","year":"2016","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.bbr.2026.116120_bib5","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0197-4580(02)00065-9","article-title":"Staging of brain pathology related to sporadic Parkinson\u2019s disease","volume":"24","author":"Braak","year":"2003","journal-title":"Neurobiol. Aging"},{"issue":"5","key":"10.1016\/j.bbr.2026.116120_bib6","first-page":"385","article-title":"A multistep validation process of biomarkers for preclinical drug development","volume":"10","author":"Freeman","year":"2010","journal-title":"Pharm. J."},{"issue":"12","key":"10.1016\/j.bbr.2026.116120_bib7","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1002\/mds.26424","article-title":"MDS clinical diagnostic criteria for Parkinson\u2019s disease","volume":"30","author":"Postuma","year":"2015","journal-title":"Mov. Disord."},{"key":"10.1016\/j.bbr.2026.116120_bib8","volume":"17","author":"Hoehn","year":"1967","journal-title":"Park. onset Progress. Mortal."},{"issue":"3","key":"10.1016\/j.bbr.2026.116120_bib9","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1136\/jnnp.55.3.181","article-title":"Accuracy of clinical diagnosis of idiopathic Parkinson\u2019s disease: a clinico-pathological study of 100 cases","volume":"55","author":"Hughes","year":"1992","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"5","key":"10.1016\/j.bbr.2026.116120_bib10","doi-asserted-by":"crossref","first-page":"103","DOI":"10.3390\/biology9050103","article-title":"Clinical features of Parkinson\u2019s disease: the evolution of critical symptoms","volume":"9","author":"V\u00e1radi","year":"2020","journal-title":"Biol."},{"issue":"5","key":"10.1016\/j.bbr.2026.116120_bib11","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1136\/jnnp.67.5.646","article-title":"Re-emergent tremor of Parkinson\u2019s disease","volume":"67","author":"Jankovic","year":"1999","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"1","key":"10.1016\/j.bbr.2026.116120_bib12","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1136\/jnnp.52.1.63","article-title":"Frozen shoulder and other shoulder disturbances in Parkinson\u2019s disease","volume":"52","author":"Riley","year":"1989","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"8","key":"10.1016\/j.bbr.2026.116120_bib13","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1002\/mds.20905","article-title":"Bilateral subthalamic nucleus deep brain stimulation improves certain aspects of postural control in Parkinson\u2019s disease, whereas medication does not","volume":"21","author":"Shivitz","year":"2006","journal-title":"Mov. Disord. Off. J. Mov. Disord. Soc."},{"issue":"1","key":"10.1016\/j.bbr.2026.116120_bib14","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1002\/mds.21813","article-title":"Nonmotor symptoms as presenting complaints in Parkinson\u2019s disease: a clinicopathological study","volume":"23","author":"O\u2019Sullivan","year":"2008","journal-title":"Mov. Disord."},{"issue":"4","key":"10.1016\/j.bbr.2026.116120_bib15","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1097\/01.nrl.0000131146.08278.a5","article-title":"Parkinson disease: an update","volume":"10","author":"Frucht","year":"2004","journal-title":"Neurologist"},{"issue":"8","key":"10.1016\/j.bbr.2026.116120_bib16","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1212\/WNL.38.8.1237","article-title":"Olfactory dysfunction in parkinsonism: a general deficit unrelated to neurologic signs, disease stage, or disease duration","volume":"38","author":"Doty","year":"1988","journal-title":"Neurology"},{"issue":"9","key":"10.1016\/j.bbr.2026.116120_bib17","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/0021-9681(75)90058-2","article-title":"Olfactory function in patients with Parkinson\u2019s disease","volume":"28","author":"Ansari","year":"1975","journal-title":"J. Chronic Dis."},{"issue":"2","key":"10.1016\/j.bbr.2026.116120_bib18","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1002\/mds.21803","article-title":"A systematic review of prevalence studies of depression in Parkinson\u2019s disease","volume":"23","author":"Reijnders","year":"2008","journal-title":"Mov. Disord."},{"issue":"6","key":"10.1016\/j.bbr.2026.116120_bib19","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1093\/brain\/awh445","article-title":"Depression in Parkinson\u2019s disease: loss of dopamine and noradrenaline innervation in the limbic system","volume":"128","author":"Remy","year":"2005","journal-title":"Brain"},{"issue":"1","key":"10.1016\/j.bbr.2026.116120_bib20","doi-asserted-by":"crossref","first-page":"145","DOI":"10.2147\/nedt.2007.3.1.145","article-title":"Prodromal non-motor symptoms of Parkinson\u2019s disease","volume":"3","author":"Pellicano","year":"2007","journal-title":"Neuropsychiatr. Dis. Treat."},{"issue":"8","key":"10.1016\/j.bbr.2026.116120_bib21","article-title":"Depression in Parkinson\u2019s disease: a narrative review","volume":"14","author":"Chikatimalla","year":"2022","journal-title":"Cureus"},{"key":"10.1016\/j.bbr.2026.116120_bib22","doi-asserted-by":"crossref","first-page":"vi24","DOI":"10.1007\/s00415-004-1606-6","article-title":"Depression and Parkinson\u2019s disease","volume":"251","author":"Lemke","year":"2004","journal-title":"J. Neurol."},{"issue":"2","key":"10.1016\/j.bbr.2026.116120_bib23","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S1474-4422(03)00307-7","article-title":"Gastrointestinal dysfunction in Parkinson\u2019s disease","volume":"2","author":"Pfeiffer","year":"2003","journal-title":"Lancet Neurol."},{"issue":"5","key":"10.1016\/j.bbr.2026.116120_bib24","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1093\/aje\/kwr119","article-title":"A prospective study of bowel movement frequency and risk of Parkinson\u2019s disease","volume":"174","author":"Gao","year":"2011","journal-title":"Am. J. Epidemiol."},{"issue":"1\u20132","key":"10.1016\/j.bbr.2026.116120_bib25","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jns.2009.08.020","article-title":"Gastrointestinal dysfunction in Parkinson\u2019s Disease","volume":"289","author":"Jost","year":"2010","journal-title":"J. Neurol. Sci."},{"issue":"2","key":"10.1016\/j.bbr.2026.116120_bib26","first-page":"255","article-title":"Linking smoking, coffee, urate, and Parkinson\u2019s disease--a role for gut microbiota?","volume":"5","author":"Scheperjans","year":"2015","journal-title":"J. Park. Dis."},{"key":"10.1016\/j.bbr.2026.116120_bib27","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/978-1-60761-429-6_21","article-title":"Visual dysfunction in Parkinson\u2019s disease","author":"Rodnitzky","year":"2013","journal-title":"Park. Dis. nonmotor Dysfunct."},{"key":"10.1016\/j.bbr.2026.116120_bib28","first-page":"144","article-title":"Ocular motility in Parkinson\u2019s disease","volume":"33","author":"Repka","year":"1996"},{"issue":"11","key":"10.1016\/j.bbr.2026.116120_bib29","first-page":"2473","article-title":"Decreased dopamine in the retinas of patients with Parkinson\u2019s disease","volume":"31","author":"Harnois","year":"1990","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"3","key":"10.1016\/j.bbr.2026.116120_bib30","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/0024-3205(88)90315-3","article-title":"Systemic 1-methyl, 4-phenyl, 1-2-3-6-tetrahydropyridine (MPTP) administration decreases retinal dopamine content in primates","volume":"43","author":"Ghilardi","year":"1988","journal-title":"Life Sci."},{"issue":"21","key":"10.1016\/j.bbr.2026.116120_bib31","doi-asserted-by":"crossref","first-page":"3421","DOI":"10.1016\/S0042-6989(97)00398-2","article-title":"Acquired colour deficiency in patients with Parkinson\u2019s disease","volume":"38","author":"Birch","year":"1998","journal-title":"Vis. Res"},{"issue":"5604","key":"10.1016\/j.bbr.2026.116120_bib32","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1126\/science.1077209","article-title":"Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism","volume":"299","author":"Bonifati","year":"2003","journal-title":"Science (80. )."},{"issue":"9","key":"10.1016\/j.bbr.2026.116120_bib33","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.3390\/jcm8091377","article-title":"DJ-1 in Parkinson\u2019s disease: clinical insights and therapeutic perspectives","volume":"8","author":"Repici","year":"2019","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.bbr.2026.116120_bib34","first-page":"67","article-title":"The multifaceted roles of DJ-1 as an antioxidant","author":"Raninga","year":"2017","journal-title":"DJ1\/PARK7 Protein Park. Dis. Cancer Oxid. Stress. Dis."},{"issue":"24","key":"10.1016\/j.bbr.2026.116120_bib35","doi-asserted-by":"crossref","first-page":"9103","DOI":"10.1073\/pnas.0402959101","article-title":"The Parkinson\u2019s disease protein DJ-1 is neuroprotective due to cysteine-sulfinic acid-driven mitochondrial localization","volume":"101","author":"Canet-Avil\u00e9s","year":"2004","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"1","key":"10.1016\/j.bbr.2026.116120_bib36","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0054087","article-title":"Monomer DJ-1 and its N-terminal sequence are necessary for mitochondrial localization of DJ-1 mutants","volume":"8","author":"Maita","year":"2013","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.bbr.2026.116120_bib37","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/j.parkreldis.2012.03.013","article-title":"The DJ-1 concentration in cerebrospinal fluid does not differentiate among Parkinsonian syndromes","volume":"18","author":"Salvesen","year":"2012","journal-title":"Park. Relat. Disord."},{"issue":"3","key":"10.1016\/j.bbr.2026.116120_bib38","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1002\/ana.22311","article-title":"Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression","volume":"69","author":"Shi","year":"2011","journal-title":"Ann. Neurol."},{"issue":"3","key":"10.1016\/j.bbr.2026.116120_bib39","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.bbrc.2006.05.011","article-title":"Increased level of DJ-1 in the cerebrospinal fluids of sporadic Parkinson\u2019s disease","volume":"345","author":"Waragai","year":"2006","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"1","key":"10.1016\/j.bbr.2026.116120_bib40","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.neulet.2010.06.009","article-title":"Significance and confounders of peripheral DJ-1 and alpha-synuclein in Parkinson\u2019s disease","volume":"480","author":"Shi","year":"2010","journal-title":"Neurosci. Lett."},{"issue":"1","key":"10.1016\/j.bbr.2026.116120_bib41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.neulet.2009.08.074","article-title":"Preparation and application of monoclonal antibodies against oxidized DJ-1. Significant elevation of oxidized DJ-1 in erythrocytes of early-stage Parkinson disease patients","volume":"465","author":"Saito","year":"2009","journal-title":"Neurosci. Lett."},{"issue":"14","key":"10.1016\/j.bbr.2026.116120_bib42","doi-asserted-by":"crossref","first-page":"3038","DOI":"10.1038\/emboj.2012.170","article-title":"Mitochondrial dysfunction in Parkinson\u2019s disease: molecular mechanisms and pathophysiological consequences","volume":"31","author":"Exner","year":"2012","journal-title":"EMBO J."},{"issue":"22","key":"10.1016\/j.bbr.2026.116120_bib43","doi-asserted-by":"crossref","first-page":"14978","DOI":"10.1074\/jbc.M808700200","article-title":"Identification of a novel Zn2+-binding domain in the autosomal recessive juvenile Parkinson-related E3 ligase parkin","volume":"284","author":"Hristova","year":"2009","journal-title":"J. Biol. Chem."},{"issue":"5","key":"10.1016\/j.bbr.2026.116120_bib44","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1042\/BST0370937","article-title":"The emerging complexity of protein ubiquitination","volume":"37","author":"Komander","year":"2009","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/j.bbr.2026.116120_bib45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2202-6-71","article-title":"Parkin-deficient mice are not more sensitive to 6-hydroxydopamine or methamphetamine neurotoxicity","volume":"6","author":"Perez","year":"2005","journal-title":"BMC Neurosci."},{"issue":"5","key":"10.1016\/j.bbr.2026.116120_bib46","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.cell.2011.02.010","article-title":"PARIS (ZNF746) repression of PGC-1$\u03b1$ contributes to neurodegeneration in Parkinson\u2019s disease","volume":"144","author":"Shin","year":"2011","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.bbr.2026.116120_bib47","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.neuroscience.2006.12.028","article-title":"Extensive nuclear localization of alpha-synuclein in normal rat brain neurons revealed by a novel monoclonal antibody","volume":"145","author":"Yu","year":"2007","journal-title":"Neuroscience"},{"issue":"5321","key":"10.1016\/j.bbr.2026.116120_bib48","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1126\/science.276.5321.2045","article-title":"Mutation in the \u03b1-synuclein gene identified in families with Parkinson\u2019s disease","volume":"276","author":"Polymeropoulos","year":"1997","journal-title":"Science (80. )"},{"issue":"6","key":"10.1016\/j.bbr.2026.116120_bib49","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1111\/jnc.12806","article-title":"Divergent effects of the H50Q and G51D SNCA mutations on the aggregation of $\u03b1$-synuclein","volume":"131","author":"Rutherford","year":"2014","journal-title":"J. Neurochem."},{"issue":"17","key":"10.1016\/j.bbr.2026.116120_bib50","doi-asserted-by":"crossref","first-page":"4491","DOI":"10.1093\/hmg\/ddu165","article-title":"The novel Parkinson\u2019s disease linked mutation G51D attenuates in vitro aggregation and membrane binding of $\u03b1$-synuclein, and enhances its secretion and nuclear localization in cells","volume":"23","author":"Fares","year":"2014","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.bbr.2026.116120_bib51","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13024-019-0329-1","article-title":"Alpha-synuclein structure and Parkinson\u2019s disease--lessons and emerging principles","volume":"14","author":"Meade","year":"2019","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.bbr.2026.116120_bib52","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/978-3-7091-6301-6_19","article-title":"Changes in cytokines and neurotrophins in Parkinson\u2019s disease","author":"Nagatsu","year":"2000","journal-title":"Adv. Res. Neurodegener."},{"issue":"6","key":"10.1016\/j.bbr.2026.116120_bib53","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1016\/j.cell.2016.11.018","article-title":"Gut microbiota regulate motor deficits and neuroinflammation in a model of Parkinson\u2019s disease","volume":"167","author":"Sampson","year":"2016","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.bbr.2026.116120_bib54","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1002\/mds.27326","article-title":"Stool immune profiles evince gastrointestinal inflammation in Parkinson\u2019s disease","volume":"33","author":"Houser","year":"2018","journal-title":"Mov. Disord."},{"issue":"1","key":"10.1016\/j.bbr.2026.116120_bib55","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.nbd.2006.06.013","article-title":"Progressive neurodegeneration and motor disabilities induced by chronic expression of IL-1$\u03b2$ in the substantia nigra","volume":"24","author":"Ferrari","year":"2006","journal-title":"Neurobiol. Dis."},{"issue":"9","key":"10.1016\/j.bbr.2026.116120_bib56","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1212\/WNL.0000000000001308","article-title":"Parkinson disease with REM sleep behavior disorder: features, $\u03b1$-synuclein, and inflammation","volume":"84","author":"Hu","year":"2015","journal-title":"Neurology"},{"issue":"1\u20132","key":"10.1016\/j.bbr.2026.116120_bib57","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/0304-3940(95)12192-7","article-title":"Interleukin-1$\u03b2$ and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer\u2019s and de novo Parkinson\u2019s disease patients","volume":"202","author":"Blum-Degena","year":"1995","journal-title":"Neurosci. Lett."},{"issue":"7","key":"10.1016\/j.bbr.2026.116120_bib58","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1002\/mds.26563","article-title":"S erum immune markers and disease progression in an incident P arkinson\u2019s disease cohort (ICICLE-PD)","volume":"31","author":"Williams-Gray","year":"2016","journal-title":"Mov. Disord."},{"issue":"1","key":"10.1016\/j.bbr.2026.116120_bib59","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/0304-3940(96)12706-3","article-title":"Interleukin (IL)-1$\u03b2$, IL-2, IL-4, IL-6 and transforming growth factor-$\u03b1$ levels are elevated in ventricular cerebrospinal fluid in juvenile parkinsonism and Parkinson\u2019s disease","volume":"211","author":"Mogi","year":"1996","journal-title":"Neurosci. Lett."},{"issue":"2","key":"10.1016\/j.bbr.2026.116120_bib60","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1006\/exnr.1996.0200","article-title":"TGF$\u03b2$1 and TGF$\u03b2$2 concentrations are elevated in Parkinson\u2019s disease in ventricular cerebrospinal fluid","volume":"142","author":"Vawter","year":"1996","journal-title":"Exp. Neurol."},{"issue":"3","key":"10.1016\/j.bbr.2026.116120_bib61","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.cyto.2012.07.030","article-title":"Inflammatory cytokines and NT-proCNP in Parkinson\u2019s disease patients","volume":"60","author":"Koziorowski","year":"2012","journal-title":"Cytokine"},{"issue":"12","key":"10.1016\/j.bbr.2026.116120_bib62","first-page":"725","article-title":"Immune factors or depression? Fatigue correlates in Parkinson\u2019s disease,\u201d Rev Neurol","volume":"45","author":"Katsarou","year":"2007"},{"issue":"2","key":"10.1016\/j.bbr.2026.116120_bib63","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.neulet.2008.06.040","article-title":"Serum interleukin (IL-2, IL-10, IL-6, IL-4), TNF$\u03b1$, and INF$\u03b3$ concentrations are elevated in patients with atypical and idiopathic parkinsonism","volume":"441","author":"Brodacki","year":"2008","journal-title":"Neurosci. Lett."},{"issue":"1","key":"10.1016\/j.bbr.2026.116120_bib64","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/j.1600-0404.1999.tb00721.x","article-title":"Association of circulating TNF-$\u03b1$ and IL-6 with ageing and parkinsonism","volume":"100","author":"Dobbs","year":"1999","journal-title":"Acta Neurol. Scand."},{"issue":"2\u20133","key":"10.1016\/j.bbr.2026.116120_bib65","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1159\/000097237","article-title":"Evaluation of interleukins, ACTH, cortisol and prolactin concentrations in the blood of patients with parkinson\u2019s disease","volume":"3","author":"Stypu\u0142a","year":"1996","journal-title":"Neuroimmunomodulation"},{"issue":"1","key":"10.1016\/j.bbr.2026.116120_bib66","doi-asserted-by":"crossref","first-page":"97","DOI":"10.5603\/PJNNS.a2020.0097","article-title":"Neutrophil-to-lymphocyte ratio (NLR) at boundaries of Progressive Supranuclear Palsy Syndrome (PSPS) and Corticobasal Syndrome (CBS)","volume":"55","author":"Alster","year":"2021","journal-title":"Neurol. Neurochir. Pol."},{"issue":"2","key":"10.1016\/j.bbr.2026.116120_bib67","doi-asserted-by":"crossref","first-page":"148","DOI":"10.5603\/PJNNS.a2022.0014","article-title":"Platelet-to-lymphocyte ratio and neutrophil-tolymphocyte ratio may reflect differences in PD and MSA-P neuroinflammation patterns","volume":"56","author":"Madetko","year":"2022","journal-title":"Neurol. Neurochir. Pol."},{"issue":"11","key":"10.1016\/j.bbr.2026.116120_bib68","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1001\/jamaneurol.2016.2742","article-title":"Aberrations in peripheral inflammatory cytokine levels in Parkinson disease: a systematic review and meta-analysis","volume":"73","author":"Qin","year":"2016","journal-title":"JAMA Neurol."},{"issue":"1\u20132","key":"10.1016\/j.bbr.2026.116120_bib69","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/0304-3940(94)90746-3","article-title":"Tumor necrosis factor-$\u03b1$ (TNF-$\u03b1$) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients","volume":"165","author":"Mogi","year":"1994","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.bbr.2026.116120_bib70","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1007\/BF01291792","article-title":"Interleukin-2 but not basic fibroblast growth factor is elevated in parkinsonian brain","volume":"103","author":"Mogi","year":"1996","journal-title":"J. Neural Transm."},{"issue":"8","key":"10.1016\/j.bbr.2026.116120_bib71","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.parkreldis.2015.05.015","article-title":"The association between infectious burden and Parkinson\u2019s disease: a case-control study","volume":"21","author":"Bu","year":"2015","journal-title":"Park. Relat. Disord."},{"issue":"4","key":"10.1016\/j.bbr.2026.116120_bib72","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.neuron.2004.11.005","article-title":"Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology","volume":"44","author":"Zimprich","year":"2004","journal-title":"Neuron"},{"issue":"6676","key":"10.1016\/j.bbr.2026.116120_bib73","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/33416","article-title":"Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism","volume":"392","author":"Kitada","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.bbr.2026.116120_bib74","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.bbi.2013.07.007","article-title":"Cerebrospinal fluid inflammatory markers in Parkinson\u2019s disease \u2013 Associations with depression, fatigue, and cognitive impairment","volume":"33","author":"Lindqvist","year":"2013","journal-title":"Brain. Behav. Immun."},{"issue":"1","key":"10.1016\/j.bbr.2026.116120_bib75","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/s41531-021-00247-x","article-title":"Cerebrospinal fluid biomarkers in Parkinson\u2019s disease with freezing of gait: an exploratory analysis","volume":"7","author":"Hatcher-Martin","year":"2021","journal-title":"NPJ Park. Dis."},{"key":"10.1016\/j.bbr.2026.116120_bib76","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12974-018-1339-6","article-title":"Cerebrospinal fluid pro-inflammatory cytokines differentiate parkinsonian syndromes","volume":"15","author":"Starhof","year":"2018","journal-title":"J. Neuroinflamm."},{"issue":"4","key":"10.1016\/j.bbr.2026.116120_bib77","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1097\/WAD.0000000000000211","article-title":"Systemic inflammation in Lewy body diseases: a systematic review","volume":"31","author":"King","year":"2017","journal-title":"Alzheimer Dis. Assoc. Disord."},{"issue":"6","key":"10.1016\/j.bbr.2026.116120_bib78","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1021\/acs.analchem.3c04849","article-title":"Intelligent identification of cerebrospinal fluid for the diagnosis of Parkinson\u2019s disease","volume":"96","author":"Chen","year":"2024","journal-title":"Anal. Chem."},{"key":"10.1016\/j.bbr.2026.116120_bib79","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.nbd.2017.04.004","article-title":"Alpha-synuclein: Pathology, mitochondrial dysfunction and neuroinflammation in Parkinson\u2019s disease","volume":"109","author":"Rocha","year":"2018","journal-title":"Neurobiol. Dis."},{"issue":"1","key":"10.1016\/j.bbr.2026.116120_bib80","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1523\/JNEUROSCI.2507-13.2014","article-title":"\u03b1-Synuclein is localized to mitochondria-associated ER membranes","volume":"34","author":"Guardia-Laguarta","year":"2014","journal-title":"J. Neurosci. Off. J. Soc. Neurosci."},{"issue":"12","key":"10.1016\/j.bbr.2026.116120_bib81","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1038\/81834","article-title":"Chronic systemic pesticide exposure reproduces features of Parkinson\u2019s disease","volume":"3","author":"Betarbet","year":"2000","journal-title":"Nat. Neurosci."},{"issue":"10","key":"10.1016\/j.bbr.2026.116120_bib82","doi-asserted-by":"crossref","first-page":"4194","DOI":"10.1073\/pnas.1100976108","article-title":"In vivo demonstration that alpha-synuclein oligomers are toxic","volume":"108","author":"Winner","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"15","key":"10.1016\/j.bbr.2026.116120_bib83","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1212\/WNL.0000000000000316","article-title":"Skin nerve $\u03b1$-synuclein deposits: a biomarker for idiopathic Parkinson disease","volume":"82","author":"Donadio","year":"2014","journal-title":"Neurology"},{"issue":"18","key":"10.1016\/j.bbr.2026.116120_bib84","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1212\/WNL.0b013e3182a9f449","article-title":"$\u03b1$-Synuclein in cutaneous autonomic nerves","volume":"81","author":"Wang","year":"2013","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.bbr.2026.116120_bib85","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1212\/WNL.0000000000002919","article-title":"The diagnostic discrimination of cutaneous $\u03b1$-synuclein deposition in Parkinson disease","volume":"87","author":"Gibbons","year":"2016","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.bbr.2026.116120_bib86","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1093\/brain\/awaa008","article-title":"$\u03b1$-Synuclein oligomers in skin biopsy of idiopathic and monozygotic twin patients with Parkinson\u2019s disease","volume":"143","author":"Mazzetti","year":"2020","journal-title":"Brain"},{"key":"10.1016\/j.bbr.2026.116120_bib87","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1007\/s00401-010-0665-2","article-title":"Lewy pathology in the submandibular gland of individuals with incidental Lewy body disease and sporadic Parkinson\u2019s disease","volume":"119","author":"Del Tredici","year":"2010","journal-title":"Acta Neuropathol."},{"issue":"12","key":"10.1016\/j.bbr.2026.116120_bib88","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1136\/gut.2008.162503","article-title":"Pathological lesions in colonic biopsies during Parkinson\u2019s disease","volume":"57","author":"Lebouvier","year":"2008","journal-title":"Gut"},{"issue":"4","key":"10.1016\/j.bbr.2026.116120_bib89","doi-asserted-by":"crossref","first-page":"e202","DOI":"10.1111\/j.1365-2982.2012.01887.x","article-title":"A comparison between colonic submucosa and mucosa to detect Lewy pathology in Parkinson\u2019s disease","volume":"24","author":"Pouclet","year":"2012","journal-title":"Neurogastroenterol. Motil."},{"key":"10.1016\/j.bbr.2026.116120_bib90","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2020.567129","article-title":"Dopamine, alpha-synuclein, and mitochondrial dysfunctions in parkinsonian eyes","volume":"14","author":"Indrieri","year":"2020","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.bbr.2026.116120_bib91","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.nbd.2018.09.013","article-title":"Accelerated accumulation of retinal $\u03b1$-synuclein (pSer129) and tau, neuroinflammation, and autophagic dysregulation in a seeded mouse model of Parkinson\u2019s disease","volume":"121","author":"Mammadova","year":"2019","journal-title":"Neurobiol. Dis."},{"issue":"2","key":"10.1016\/j.bbr.2026.116120_bib92","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1159\/000112832","article-title":"Red blood cells are the major source of alpha-synuclein in blood","volume":"5","author":"Barbour","year":"2008","journal-title":"Neurodegener. Dis."},{"key":"10.1016\/j.bbr.2026.116120_bib93","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.3389\/fneur.2019.01388","article-title":"Plasma and serum alpha-synuclein as a biomarker of diagnosis in patients with Parkinson\u2019s disease","volume":"10","author":"Chang","year":"2020","journal-title":"Front Neurol."},{"key":"10.1016\/j.bbr.2026.116120_bib94","first-page":"10470","article-title":"Levels of oligomeric alpha-synuclein in red blood cells are elevated in patients with Parkinson\u2019s disease and affected by brain alpha-synuclein expression","volume":"12","author":"Li","year":"2019","journal-title":"Int. J. Clin. Exp. Med"},{"issue":"1","key":"10.1016\/j.bbr.2026.116120_bib95","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ultrasmedbio.2006.07.021","article-title":"Transcranial brain parenchyma sonography in movement disorders: state of the art","volume":"33","author":"Walter","year":"2007","journal-title":"Ultrasound Med. Biol."},{"issue":"2","key":"10.1016\/j.bbr.2026.116120_bib96","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.neuroimage.2007.12.019","article-title":"Contemporary ultrasound systems allow high-resolution transcranial imaging of small echogenic deep intracranial structures similarly as MRI: a phantom study","volume":"40","author":"Walter","year":"2008","journal-title":"Neuroimage"},{"issue":"11","key":"10.1016\/j.bbr.2026.116120_bib97","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/S1474-4422(08)70239-4","article-title":"Transcranial sonography in movement disorders","volume":"7","author":"Berg","year":"2008","journal-title":"Lancet Neurol."},{"issue":"2","key":"10.1016\/j.bbr.2026.116120_bib98","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/S1053-8119(02)00035-6","article-title":"Echogenicity of the substantia nigra in relatives of patients with sporadic Parkinson\u2019s disease","volume":"18","author":"Ruprecht-D\u00f6rfler","year":"2003","journal-title":"Neuroimage"},{"issue":"3","key":"10.1016\/j.bbr.2026.116120_bib99","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/S0165-0173(01)00056-X","article-title":"Rethinking the role of ceruloplasmin in brain iron metabolism","volume":"35","author":"Qian","year":"2001","journal-title":"Brain Res. Rev."},{"issue":"6","key":"10.1016\/j.bbr.2026.116120_bib100","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1093\/sleep\/31.6.847","article-title":"Altered iron metabolism in lymphocytes from subjects with restless legs syndrome","volume":"31","author":"Earley","year":"2008","journal-title":"Sleep"},{"issue":"3","key":"10.1016\/j.bbr.2026.116120_bib101","first-page":"77","article-title":"MRI findings in movement disorders and associated sleep disturbances","volume":"13","author":"Ghaderi","year":"2023","journal-title":"Am. J. Nucl. Med. Mol. Imaging"},{"issue":"4","key":"10.1016\/j.bbr.2026.116120_bib102","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1177\/1756285613511507","article-title":"A review of the use of magnetic resonance imaging in Parkinson\u2019s disease","volume":"7","author":"Pyatigorskaya","year":"2014","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.bbr.2026.116120_bib103","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.neulet.2017.02.056","article-title":"Identifying the presence of Parkinson\u2019s disease using low-frequency fluctuations in BOLD signals","volume":"645","author":"Tang","year":"2017","journal-title":"Neurosci. Lett."},{"issue":"1","key":"10.1016\/j.bbr.2026.116120_bib104","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1073\/pnas.95.1.322","article-title":"The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity","volume":"95","author":"de Lecea","year":"1998","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.bbr.2026.116120_bib105","doi-asserted-by":"crossref","DOI":"10.1016\/j.peptides.2021.170713","article-title":"Parkinson disease: Protective role and function of neuropeptides","volume":"151","author":"Tabikh","year":"2022","journal-title":"Peptides"},{"issue":"6","key":"10.1016\/j.bbr.2026.116120_bib106","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1093\/brain\/awm090","article-title":"Hypocretin (orexin) loss in Parkinson\u2019s disease","volume":"130","author":"Fronczek","year":"2007","journal-title":"Brain"},{"issue":"6","key":"10.1016\/j.bbr.2026.116120_bib107","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1093\/brain\/awm097","article-title":"Hypocretin (orexin) cell loss in Parkinson\u2019s disease","volume":"130","author":"Thannickal","year":"2007","journal-title":"Brain"},{"issue":"8","key":"10.1016\/j.bbr.2026.116120_bib108","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.neuint.2013.09.022","article-title":"Protective effect of orexin-A on 6-hydroxydopamine-induced neurotoxicity in SH-SY5Y human dopaminergic neuroblastoma cells","volume":"63","author":"Esmaeili-Mahani","year":"2013","journal-title":"Neurochem. Int."},{"issue":"2","key":"10.1016\/j.bbr.2026.116120_bib109","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.neulet.2009.06.012","article-title":"Deficiency of Vlgr1 resulted in deafness and susceptibility to audiogenic seizures while the degree of hearing impairment was not correlated with seizure severity in C57BL\/6-and 129-backcrossed lines of Vlgr1 knockout mice","volume":"461","author":"Yagi","year":"2009","journal-title":"Neurosci. Lett."},{"issue":"1","key":"10.1016\/j.bbr.2026.116120_bib110","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.expneurol.2010.08.005","article-title":"Sleep alterations in an environmental neurotoxin-induced model of parkinsonism","volume":"226","author":"McDowell","year":"2010","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.bbr.2026.116120_bib111","doi-asserted-by":"crossref","DOI":"10.1016\/j.expneurol.2019.113110","article-title":"Depletion of hypothalamic hypocretin\/orexin neurons correlates with impaired memory in a Parkinson\u2019s disease animal model","volume":"323","author":"Oliveira","year":"2020","journal-title":"Exp. Neurol."},{"issue":"1","key":"10.1016\/j.bbr.2026.116120_bib112","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/ejn.12761","article-title":"Sparing of orexin-A and orexin-B neurons in the hypothalamus and of orexin fibers in the substantia nigra of 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-treated macaques","volume":"41","author":"Bensaid","year":"2015","journal-title":"Eur. J. Neurosci."},{"issue":"1","key":"10.1016\/j.bbr.2026.116120_bib113","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1146\/annurev.neuro.29.051605.112839","article-title":"Noncoding RNAs in the mammalian central nervous system","volume":"29","author":"Cao","year":"2006","journal-title":"Annu. Rev. Neurosci."},{"issue":"23","key":"10.1016\/j.bbr.2026.116120_bib114","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.4155\/bio-2016-0166","article-title":"Recent developments in circulating biomarkers in Parkinson\u2019s disease: the potential use of miRNAs in a clinical setting","volume":"8","author":"Teixeira Dos Santos","year":"2016","journal-title":"Bioanalysis"},{"key":"10.1016\/j.bbr.2026.116120_bib115","doi-asserted-by":"crossref","first-page":"36","DOI":"10.3389\/fnagi.2016.00036","article-title":"microRNA profiles in Parkinson\u2019s disease prefrontal cortex","volume":"8","author":"Hoss","year":"2016","journal-title":"Front. Aging Neurosci."},{"issue":"11","key":"10.1016\/j.bbr.2026.116120_bib116","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1001\/archneurol.2012.1654","article-title":"Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and\/or parkinsonian disorders","volume":"69","author":"Hall","year":"2012","journal-title":"Arch. Neurol."},{"issue":"1\u20132","key":"10.1016\/j.bbr.2026.116120_bib117","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jns.2011.06.046","article-title":"\\\u2019\\i, \u201cAmyloid-$\u03b2$ and $\u03c4$ biomarkers in Parkinson\u2019s disease--dementia","volume":"310","author":"Buongiorno","year":"2011","journal-title":"J. Neurol. Sci."},{"issue":"4","key":"10.1016\/j.bbr.2026.116120_bib118","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s00702-011-0736-0","article-title":"CSF biomarkers in different phenotypes of Parkinson disease","volume":"119","author":"Jellinger","year":"2012","journal-title":"J. Neural Transm."},{"issue":"1","key":"10.1016\/j.bbr.2026.116120_bib119","article-title":"S100B protein, a damage-associated molecular pattern protein in the brain and heart, and beyond","volume":"2010","author":"Sorci","year":"2010","journal-title":"Cardiovasc. Psychiatry Neurol."},{"key":"10.1016\/j.bbr.2026.116120_bib120","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.nbd.2017.07.014","article-title":"Cytokine profiling in the prefrontal cortex of Parkinson\u2019s disease and multiple system atrophy patients","volume":"106","author":"Rydbirk","year":"2017","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.bbr.2026.116120_bib121","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1007\/s00109-007-0233-y","article-title":"Cannabinoid CB 1 receptor stimulation affords neuroprotection in MPTP-induced neurotoxicity by attenuating S100B up-regulation in vitro","volume":"85","author":"Iuvone","year":"2007","journal-title":"J. Mol. Med."},{"issue":"11","key":"10.1016\/j.bbr.2026.116120_bib122","doi-asserted-by":"crossref","first-page":"3336","DOI":"10.1093\/brain\/aws250","article-title":"S100B is increased in Parkinson\u2019s disease and ablation protects against MPTP-induced toxicity through the RAGE and TNF-$\u03b1$ pathway","volume":"135","author":"Sathe","year":"2012","journal-title":"Brain"},{"issue":"4","key":"10.1016\/j.bbr.2026.116120_bib123","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1080\/00207450590521064","article-title":"Glial bFGF and S100 immunoreactivities increase in ascending dopamine pathways following striatal 6-OHDA-induced partial lesion of the nigrostriatal system: a sterological analysis","volume":"115","author":"Gomide","year":"2005","journal-title":"Int. J. Neurosci."},{"issue":"1","key":"10.1016\/j.bbr.2026.116120_bib124","article-title":"Striatal injury with 6-OHDA transiently increases cerebrospinal GFAP and S100B","volume":"2015","author":"Batassini","year":"2015","journal-title":"Neural Plast."}],"container-title":["Behavioural Brain Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166432826000963?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166432826000963?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,17]],"date-time":"2026-05-17T08:29:20Z","timestamp":1779006560000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166432826000963"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":124,"alternative-id":["S0166432826000963"],"URL":"https:\/\/doi.org\/10.1016\/j.bbr.2026.116120","relation":{},"ISSN":["0166-4328"],"issn-type":[{"value":"0166-4328","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Parkinson\u2019s disease biomarkers: bridging the gap between diagnosis and treatment","name":"articletitle","label":"Article Title"},{"value":"Behavioural Brain Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbr.2026.116120","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"116120"}}